Back to Results

ImageneBio Inc (IMA)

ImageneBio, Inc. (NASDAQ: IMA) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with immunological, autoimmune, and inflammatory diseases. The company’s lead candidate is IMG-007, a non-depleting anti-OX40 monoclonal antibody designed to bind the OX40 receptor on activated T cells and prevent interaction with the OX40 ligand. IMG-007 is currently being evaluated in a Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and adopted the ImageneBio name in July 2025. ImageneBio is headquartered in San Diego, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-IMA
$5.90
21.7% Upside
Undervalued
$18
271.1% Upside
Bargain
Weak
0.0%
November 11, 2026
0.4x
55.055 M
-79.64 M
3.4%
51.4%
16.0
98.6%
Valuation • Fair Value

ImageneBio Inc (NASDAQ-IMA) Fair Value by Valuation Model

Review the available estimates for ImageneBio Inc (NASDAQ-IMA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$5.90

Estimated upside of 21.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$5.90

Comparable-company valuation reference.

Analyst Price Target

$18

Analysts imply upside of 271.1%.

How to read these valuation models

Use the 4 available valuation references for ImageneBio Inc (NASDAQ-IMA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for ImageneBio Inc (NASDAQ-IMA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

0 K

Current operating scale indicator.

Revenue Forecast

800 K

Forward revenue estimate.

EBITDA

-58.367 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review ImageneBio Inc (NASDAQ-IMA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ImageneBio Inc (NASDAQ-IMA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

16.0

Relatively strong balance-sheet zone.

FCF / Net Income

98.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ImageneBio Inc (NASDAQ-IMA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for ImageneBio Inc (NASDAQ-IMA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for ImageneBio Inc (NASDAQ-IMA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

ImageneBio Inc (NASDAQ-IMA) Stock Forecast & Technical Outlook

Review ImageneBio Inc (NASDAQ-IMA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for ImageneBio Inc (NASDAQ-IMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for ImageneBio Inc (NASDAQ-IMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for ImageneBio Inc (NASDAQ-IMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for ImageneBio Inc (NASDAQ-IMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for ImageneBio Inc (NASDAQ-IMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for ImageneBio Inc (NASDAQ-IMA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, ImageneBio Inc (NASDAQ-IMA) has a Strong Buy consensus, with 3 buy, 0 hold and 1 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 1
FAQ • Fast Investor Answers

ImageneBio Inc (NASDAQ-IMA) Stock FAQ

Data-supported answers about ImageneBio Inc (NASDAQ-IMA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.90
Estimated upside 21.7%
Valuation Rating
Undervalued
Estimated upside of 21.7%
Analyst Target
$18
Implied upside 271.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for ImageneBio Inc (NASDAQ-IMA) is $5.90. This implies an estimated upside of 21.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 21.7% versus the current market price.

The available analyst price target for ImageneBio Inc (NASDAQ-IMA) is $18. The analyst target implies estimated upside of 271.1%.

The current financial health read for ImageneBio Inc (NASDAQ-IMA) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for ImageneBio Inc (NASDAQ-IMA) is November 11, 2026.

The latest available data indicates no current dividend yield for ImageneBio Inc (NASDAQ-IMA).

The current market capitalization listed for ImageneBio Inc is 55.055 M.

The current enterprise value listed for ImageneBio Inc is -79.64 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for ImageneBio Inc is NASDAQ-IMA, and the stock is listed on NASDAQ.

ImageneBio Inc (NASDAQ-IMA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for ImageneBio Inc is 3.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for ImageneBio Inc is 51.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B